Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1226

Sort by

Sort Order Select

Journal Articles

Primary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment

Blood (2025) 146 (Supplement 2): LBA-2.

https://doi.org/10.1182/blood-2025-LBA-2

Published: 2025

Journal Articles

The novel allosteric NEK7 inhibitor ofirnoflast (HT-6184) demonstrates robust and sustained hematologic response in subjects with IPSS-R very low, low or intermediate risk myelodysplastic syndrome (MDS) and symptomatic anemia

Varun Bafna, Sandip Shah, Arijit Nag, Prof. Uttam Kumar Nath, Chandran Nair, Ramesh Uppada, Devan Bursey, Andrea Groen, Victoria Allgood, Alan List, Stephen Anthony, David Bearss

Blood (2025) 146 (Supplement 1): 5622.

https://doi.org/10.1182/blood-2025-5622

Published: 2025

Journal Articles

Evaluation of response assessment in chronic lymphocytic leukaemia using measurable residual disease by flow cytometry: Prospective observational study.

Karthik Jayalingappa, Bhawana Adhikari, Prisla Dalton, Bivant Shah, Kavya Ronanki, Paras Satadeve, Adamya Gupta, Reshma Benson, Arjun Kachhwaha, Shalini Singh, Manisha Naithani, Neha Singh, Prof. Uttam Kumar Nath

Blood (2025) 146 (Supplement 1): 7438.

https://doi.org/10.1182/blood-2025-7438

Published: 2025

Journal Articles

Predictive significance of early bone marrow MRD response assessment in Acute Myeloid Leukemia patients treated with venetoclax plus decitabine induction therapy: Real-world data from India

Arjun Kachhwaha, Mmcmedicine Benson, Paras Satadeve, Adamya Gupta, Bivant Shah, Prisla Dalton, Kavya Ronanki, Karthik Kumar, Sashi Singh, Jhasaketan Nayak, Nikhil Nagpal, Neha Singh, Harish Chandra, Prof. Uttam Kumar Nath

Blood (2025) 146 (Supplement 1): 7043.

https://doi.org/10.1182/blood-2025-7043

Published: 2025

Journal Articles

Real-world impact of high-risk cytogenetics and revised ISS (R2 ISS) on response and survival in multiple myeloma patients treated with various induction regimens: A single-center study from India.

Bibhant Shah, Kavya Ronanki, Prisla Dalton, Arjun Kachhwaha, Reshma Benson, Nikhil Nagpal, Paras Satadeve, Adamya Gupta, Karthik Jayalingappa, Prof. Uttam Kumar Nath

Blood (2025) 146 (Supplement 1): 8149.

https://doi.org/10.1182/blood-2025-8149

Published: 2025

Journal Articles

CD19 expression is preserved following CD19-directed monoclonal antibody therapy with tafasitamab

Johannes Duell, Diana Alvarez Arias, Wolfram Klapper, Sarah Reinke, Florian Eisele, Thomas Larsen, Prof. Dr. Max S Topp, Beth Rumberger, TaeHyung (Simon) Kim, Andreas Rosenwald, Hilka Rauert-Wunderlich

Blood (2025) 146 (Supplement 1): 5515.

https://doi.org/10.1182/blood-2025-5515

Published: 2025

Journal Articles

Pembro-CORE: Interim analysis of a phase II PET-adapted trial omitting high-dose chemotherapy with PD-1-based salvage in first-relapsed Hodgkin lymphoma

Hishan Tharmaseelan, Sarah Gillessen, Ina Bühnen, Carsten Kobe, Karin G. Schrenk, Prof. Dr. Max S Topp, Ulf Schnetzke, Nico Freund, Stephanie Sasse, Philipp Ernst, Tanja Zamrik, Wolfram Klapper, Michael Fuchs, Sven Borchmann, Paul Bröckelmann, Peter Borchmann, Bastian von Tresckow

Blood (2025) 146 (Supplement 1): 5401.

https://doi.org/10.1182/blood-2025-5401

Published: 2025

Journal Articles

Safety and efficacy of surovatamig (AZD0486) in adolescent and adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Updated Results from the Phase 1/2 SYRUS study

Blood (2025) 146 (Supplement 1): 3345.

https://doi.org/10.1182/blood-2025-3345

Published: 2025

Journal Articles

SOUNDTRACK-B: A phase 2 single-arm study to evaluate the efficacy and safety of surovatamig (AZD0486) in relapsed or refractory B-cell non-Hodgkin lymphoma

Chan Cheah, Monique Menzies Wojtowicz, Catherine Thieblemont, Martin Hutchings, Prof. Dr. Max S Topp, Won-Seog Kim, Dai Maruyama, Azadeh Shohoudi, Robin Lesley, Wendy Chang, Marlene Zuraek, Mihail Obrocea, Jing-Zhou Hou

Blood (2025) 146 (Supplement 1): 3747.

https://doi.org/10.1182/blood-2025-3747

Published: 2025

Journal Articles

Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and adverse outcome of CAR-T therapy

Blood (2025) 146 (Supplement 1): 809.

https://doi.org/10.1182/blood-2025-809

Published: 2025

Journal Articles

A Phase 1 study of KITE-753 or KITE-363 in patients with relapsed/refractory B-cell lymphoma: Initial safety and preliminary efficacy of KITE-753 and updated results of KITE-363

Blood (2025) 146 (Supplement 1): 265.

https://doi.org/10.1182/blood-2025-265

Published: 2025

Journal Articles

Zilovertamab vedotin plus R-CHP versus polatuzumab vedotin plus R-CHP as first-line therapy in participants with germinal center B-cell diffuse large B-cell lymphoma (DLBCL): The randomized, open-label, Phase 2 waveline-011 Study

Prof. Dr. Max S Topp, Guoqing Wang, Puja Patel, Rushdia Yusuf, David Lavie

Blood (2025) 146 (Supplement 1): 5480.

https://doi.org/10.1182/blood-2025-5480

Published: 2025

Journal Articles

Long-term rusfertide treatment in polycythemia vera: Initial results from the phase 2 THRIVE extension study

Naveen Pemmaraju, Andrew Kuykendall, Ellen Ritchie, Jason Gotlib, Jeanne Palmer, Aaron Gerds, David Oubre, Prof. Uttam Kumar Nath, Gregory Vosganian, Suneel Gupta, Pedro Oyuela, Sarita Khanna, Arturo Molina, Marina Kremyanskaya

Blood (2025) 146 (Supplement 1): 3810.

https://doi.org/10.1182/blood-2025-3810

Published: 2025

Journal Articles

Dynamic changes in myeloid derived suppressor cells subsets in pediatric B cell acute lymphoblastic leukemia : Correlation with measurable residual disease status.

Prisla Dalton, Kavya Ronanki, Bivant Shah, Nikhil Nagpal, Mmcmedicine Benson, Arjun Kachhwaha, Adamya Gupta, Paras Satadeve, Neha Singh, Prof. Uttam Kumar Nath

Blood (2025) 146 (Supplement 1): 1598.

https://doi.org/10.1182/blood-2025-1598

Published: 2025

Journal Articles

Comparison of consecutive versus alternate day schedules of high-dose cytarabine consolidation chemotherapy in Acute Myeloid Leukemia: Single-center randomized controlled trial from India

Kavya Ronanki, Bibhant Shah, Prisla Dalton, Adamya Gupta, Paras Satadeve, Reshma Benson, Arjun Kachhwaha, Nikhil Nagpal, Amit Sehrawat, Karthik Kumar, Karthik Jayalingappa, Anusha Mritunjayswamy, Mayank Kapoor, Prof. Uttam Kumar Nath

Blood (2025) 146 (Supplement 1): 1687.

https://doi.org/10.1182/blood-2025-1687

Published: 2025

Journal Articles

Mucosal calprotectin is associated with severity of aGI-GVHD and poor outcomes after allogeneic stem cell transplantation

Blood blood.2025029402.

https://doi.org/10.1182/blood.2025029402

Published: 2025

Includes: Supplemental data

Journal Articles

IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax: Report of the UK NCRI FLAIR Study

Blood (2024) 144 (Supplement 1): 585.

https://doi.org/10.1182/blood-2024-211449

Published: 2024

Journal Articles

Measurable Residual Disease Results & Survival with Augmented Early Intensification Therapy in Intermediate-Risk & High-Risk Group Pediatric Acute Lymphoblastic Leukemia Patients Treated with ALL IC-BFM 2009 Protocol: A Single-Center Study from India

Prof. Uttam Kumar Nath, Karthik Kumar, Adamya Gupta, Reshma Benson, DR Arjun Kachhwaha

Blood (2023) 142 (Supplement 1): 2881.

https://doi.org/10.1182/blood-2023-188377

Published: 2023

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study from the Société Francophone De Greffe De Moelle Et Thérapie Cellulaire (SFGM-TC)

Blood (2023) 142 (Supplement 1): 2235.

https://doi.org/10.1182/blood-2023-184383

Published: 2023

Journal Articles

Balancing the Bleeding Risk & Treatment Related Complications in Immune Thrombocytopenia - an Unmet Need: Real-World Data from India

Debranjani Chattopadhyay, Anamika Bakliwal, Sudeep Vaniyath, Rituparna Chetia, Gaurav Dhingra, Prof. Uttam Kumar Nath

Blood (2022) 140 (Supplement 1): 11257–11258.

https://doi.org/10.1182/blood-2022-171185

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Primary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment

The novel allosteric NEK7 inhibitor ofirnoflast (HT-6184) demonstrates robust and sustained hematologic response in subjects with IPSS-R very low, low or intermediate risk myelodysplastic syndrome (MDS) and symptomatic anemia

Evaluation of response assessment in chronic lymphocytic leukaemia using measurable residual disease by flow cytometry: Prospective observational study.

Predictive significance of early bone marrow MRD response assessment in Acute Myeloid Leukemia patients treated with venetoclax plus decitabine induction therapy: Real-world data from India

Real-world impact of high-risk cytogenetics and revised ISS (R2 ISS) on response and survival in multiple myeloma patients treated with various induction regimens: A single-center study from India.

CD19 expression is preserved following CD19-directed monoclonal antibody therapy with tafasitamab

Pembro-CORE: Interim analysis of a phase II PET-adapted trial omitting high-dose chemotherapy with PD-1-based salvage in first-relapsed Hodgkin lymphoma

Safety and efficacy of surovatamig (AZD0486) in adolescent and adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Updated Results from the Phase 1/2 SYRUS study

SOUNDTRACK-B: A phase 2 single-arm study to evaluate the efficacy and safety of surovatamig (AZD0486) in relapsed or refractory B-cell non-Hodgkin lymphoma

Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and adverse outcome of CAR-T therapy

A Phase 1 study of KITE-753 or KITE-363 in patients with relapsed/refractory B-cell lymphoma: Initial safety and preliminary efficacy of KITE-753 and updated results of KITE-363

Zilovertamab vedotin plus R-CHP versus polatuzumab vedotin plus R-CHP as first-line therapy in participants with germinal center B-cell diffuse large B-cell lymphoma (DLBCL): The randomized, open-label, Phase 2 waveline-011 Study

Long-term rusfertide treatment in polycythemia vera: Initial results from the phase 2 THRIVE extension study

Dynamic changes in myeloid derived suppressor cells subsets in pediatric B cell acute lymphoblastic leukemia : Correlation with measurable residual disease status.

Comparison of consecutive versus alternate day schedules of high-dose cytarabine consolidation chemotherapy in Acute Myeloid Leukemia: Single-center randomized controlled trial from India

Mucosal calprotectin is associated with severity of aGI-GVHD and poor outcomes after allogeneic stem cell transplantation

IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax: Report of the UK NCRI FLAIR Study

Measurable Residual Disease Results & Survival with Augmented Early Intensification Therapy in Intermediate-Risk & High-Risk Group Pediatric Acute Lymphoblastic Leukemia Patients Treated with ALL IC-BFM 2009 Protocol: A Single-Center Study from India

Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study from the Société Francophone De Greffe De Moelle Et Thérapie Cellulaire (SFGM-TC)

Balancing the Bleeding Risk & Treatment Related Complications in Immune Thrombocytopenia - an Unmet Need: Real-World Data from India

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only